We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Arena’s Belviq Avoids a REMS, But Saddled With Six Postmarket Studies
Arena’s Belviq Avoids a REMS, But Saddled With Six Postmarket Studies
June 29, 2012
The FDA has approved its first weight-loss drug in 13 years, giving the OK to Arena Pharmaceutical’s Belviq, while requiring a hefty dose of postmarket studies on cardiovascular events.